Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus

Group 1 - Atai Life Sciences (NASDAQ: ATAI) reported results from its phase 2b study of inidascamine for treating cognitive impairment associated with schizophrenia, indicating a negative outcome [2] - The company is part of the Biotech Analysis Central service, which provides extensive analysis and a model portfolio of biotech stocks [2] Group 2 - The article emphasizes the importance of informed decision-making for healthcare investors through detailed analysis and news reports [2]